SCHEMBL10244761

SCHEMBL10244761

CCCCNC(=O)c1nccc2ncccc12

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.49
HTT P42858 2/20 0.48
TSHR P16473 1/20 0.48
RAB9A P51151 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46
NAAA Q02083 2/20 0.46
NPC1 O15118 1/20 0.45
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA5 P31644 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA2 P47869 1/20 0.45
ALDH1A1 P00352 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NAMPT P43490 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10245110 0.82 RAB9A (0.67) SMN1; SMN2HTTTSHRRAB9ANPC1
SCHEMBL10244776 0.81 NSD2 (0.64) SMN1; SMN2HTTTSHRRXFP1NAAA
SCHEMBL8358319 0.80 EGLN2 (0.61) SMN1; SMN2HTTTSHRRAB9ANAAA
SCHEMBL5264599 0.80 HTT (0.53) SMN1; SMN2HTTTSHRRAB9ARXFP1
SCHEMBL10243020 0.80 HTT (0.60) SMN1; SMN2HTTTSHRRXFP1NAAA
SCHEMBL30131475 0.79 HPGD (0.60) SMN1; SMN2HTTTSHRRAB9ANAAA
SCHEMBL5020895 0.78 RAB9A (0.66) HTTTSHRRAB9ANAAAALDH1A1
SCHEMBL9206936 0.77 HTT (0.56) SMN1; SMN2HTTTSHRRAB9ANAAA
SCHEMBL10245901 0.77 HTT (0.56) SMN1; SMN2HTTTSHRRXFP1NAAA
SCHEMBL31047590 0.76 NSD2 (0.61) SMN1; SMN2HTTTSHRNAAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 SMN1; SMN2 3120/4885HTT 868/4885TSHR 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.